can anyone provide me with information regrading the following comment from Dr. Gallen:
"We are encouraged by what we've learned from MK-6721 and are continuing our productive collaboration with Merck to focus on improving the pharm properities of our compounds to produce best in class pain treatment."
I'm curious as to the details in:
1. what was learned in the study, i cant find too many details anywhere?*
2. what improvements have been made? *
i know the bioavability has a "6 fold" improvement, but what does this mean exactly?
I also believe that if z160 phase II is successful, Merck will have first dibs
lots of notes that due to confidentiality terms in agreement with merck the info cannot be shared...
one other note stated by Gallen is that in order for it to be effective the drug needed to act long enough and have enough potency to be made in smaller pills ... due to the recent patents and potency annoucements with z160, one would be inclined to think that Zalicus already knows the trial will be successful ...
One would think that wither its bioavability, potency or any other preliminary facture the result must have already been known, based on Gallen leaving 1,200,00 shares.He could of cashed out at
minimum $1.05 per share=or $1,260,000 vs $750000.